Загрузка...
Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor
Imatinib mesylate, as treatment for gastrointestinal stromal tumors (GIST), has dramatically changed the prognosis for survival – not only because it is efficacious, but also because it attracted attention to this malignant disease. GIST is now a well-known disease entity and a paradigm for targeted...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
S. Karger AG
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3220906/ https://ncbi.nlm.nih.gov/pubmed/22114577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000333471 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|